COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study.
Bratisl Lek Listy
; 123(2): 120-124, 2022.
Article
in English
| MEDLINE | ID: covidwho-1643736
ABSTRACT
BACKGROUND:
Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS).METHODS:
A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCRpositive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records.RESULTS:
A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection.CONCLUSION:
Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiphospholipid Syndrome
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Bratisl Lek Listy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS